


S/N 10/032,376



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|-------------|--|-----------------|----------------|
| Applicant: | Stephen Quirk | Examiner: | Maury A. Audet |
| Serial No.: | 10/032,376 | Group Art Unit: | 1654 |
| Filed: | December 21, 2001 | Docket: | 1443.008US1 |
| Title: | METALLOPROTEINASE INHIBITORS FOR WOUND HEALING | | |

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(c)(2), Applicants have included the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 19-0743.

Pursuant to 37 C.F.R. 1.98(a)(2), Applicant believes that copies of cited U.S. Patents and Published Applications are no longer required to be provided to the Office. Notification of this change was provided in the United States Patent and Trademark Office OG Notices dated October 12, 2004. Thus, Applicant has not included copies of any US Patents or Published Applications cited with this submission. Should the Office require copies to be provided, Applicant respectfully requests that notice of such requirement be directed to Applicant's below-signed representative. Applicant acknowledges the requirement to submit copies of foreign patent documents and non-patent literature in accordance with 37 C.F.R. 1.98(a)(2).

09/12/2005 ERYALEW1 00000079 10032376

180.00 OP
01 FC:1806

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

STEPHEN QUIRK

By his Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(516) 795-6820




Date September 7, 2005


By _____
Robin A. Chadwick
Reg. No. 36,477

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 7th day of September, 2005.

CANDIS BUENDING
Name


Signature

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)



Sheet 1 of 2

Complete if Known

| | |
|-----------------------------|-------------------|
| Application Number | 10/032,376 |
| Filing Date | December 21, 2001 |
| First Named Inventor | Quirk, Stephen |
| Group Art Unit | 1654 |
| Examiner Name | Audet, Maury |

Attorney Docket No: 1443.008US1

US PATENT DOCUMENTS

| Examiner Initial * | USP Document Number | Publication Date | Name of Patentee or Applicant of cited Document | Filing Date If Appropriate |
|--------------------|---------------------|------------------|---|----------------------------|
| | US-2003/0012794A1 | 01/16/2003 | Srivastava, P. K., et al. | 08/02/2002 |
| | US-2004/0010001A1 | 01/15/2004 | Au, J. L., et al. | 06/18/2003 |
| | US-6,482,802 | 11/19/2002 | Hu, G.-F. , et al. | 11/09/2000 |
| | US-6,906,036 | 06/14/2005 | Quirk, S. , et al. | 05/21/2002 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Foreign Document No | Publication Date | Name of Patentee or Applicant of cited Document | T ² |
|--------------------|---------------------|------------------|---|----------------|
| | WO-0074634A2 | 12/14/2000 | Au, J. L., et al. | |
| | WO-03018748A2 | 03/06/2003 | Quirk, S. , et al. | |
| | WO-9834641A1 | 08/13/1998 | Srivastava, P. K., et al. | |
| | WO-9958126A1 | 11/18/1999 | Hu, G.-F. , et al. | |

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|----------------------|---|----------------|
| | | COPPOLA, G. , et al., "Effect of Intraperitoneally, Intravenously and Intralesionally Administered Monoclonal Anti-Beta-FGF Antibodies on Rat Chondrosarcoma Tumour Vascularization and Growth", <u>Anticancer Research</u> , 17(3C), (1997),2033-2040 | |
| | | DAILEY, L. , et al., "A Network of Transcriptional and Signaling Events is Activated by FGF to Induce Chondrocyte Growth Arrest and Differentiation", <u>The Journal of Cell Biology</u> , 161(6), (2003),1053-1066 | |
| | | FUJISAWA, N. , et al., "Inhibitory Effects of Transforming Growth Factor - Beta1 Pretreatment on Experimental Pulmonary Metastasis of MCS-1 Chinese Hamster Mesenchymal Chondrosarcoma Cells", <u>Tohoku J. Exp. Med.</u> , 187, (1999),203-213 | |
| | | GIGANT-HUSELSTEIN, C. , et al., "In vitro Study of Intracellular IL-1 Beta Production and Beta 1 Integrins Expression in Stimulated Chondrocytes - Effect of Rhein", <u>Biorheology</u> , 39(1, 2), (2002),277-285 | |

EXAMINER


DATE CONSIDERED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

| | |
|-----------------------------|-------------------|
| Application Number | 10/032,376 |
| Filing Date | December 21, 2001 |
| First Named Inventor | Quirk, Stephen |
| Group Art Unit | 1654 |
| Examiner Name | Audet, Maury |

Sheet 2 of 2

Attorney Docket No: 1443.008US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|-----------------------|--------------------------|---|----------------|
| | | KEARNS, A. E., "Initiation of Chondroitin Sulfate Biosynthesis: A Kinetic Analysis of UDP-d-Xylose: Core Protein Beta-D-Xylosyltransferase", <u>Biochemistry</u> , 30(30), (1991),7477-7483 | |
| | | LIACINI, A. , et al., "Induction of Matrix Metalloproteinase-13 Gene Expression by TNF-alpha is Mediated by MAP Kinases, AP-1, and NF-kB Transcription Factors in Articular Chondrocytes", <u>Experimental Cell Research</u> , 288(1), (2003),208-217 | |
| | | RAUCCI, A. , et al., "Activation of the ERK1/2 and p38 Mitogen-Activated Protein Kinase Pathways Mediates Fibroblast Growth Factor-Induced Growth Arrest of Chondrocytes", <u>The Journal of Biological Chemistry</u> , 279(3), (2004),1747-1756 | |
| | | RODRIGUEZ-MANZANEQUE, J. C., et al., "ADAMTS1 Cleaves Aggrecan at Multiple Sites and is Differentially Inhibited by Metalloproteinase Inhibitors", <u>Biochemical and Biophysical Research Communications</u> , 293(1), (2002),501-508 | |
| | | SAHNI, M. , et al., "FGF Signaling Inhibits Chondrocyte Proliferation and Regulates Bone Development Through the STAT-1 Pathway", <u>Genes & Development</u> , 13(11), (1999),1361-1366 | |
| | | SEONG, S.-C. , et al., "Insulin-Like Growth Factor I Regulation of Swarm Rat Chondrosarcoma Chondrocytes in Culture", <u>Experimental Cell Research</u> , 211, (1994),238-244 | |
| | | WU, C. , et al., "Furin-Mediated Processing of Pro-C-Type Natriuretic Peptide", <u>The Journal of Biological Chemistry</u> , 278(28), (2003),25847-25852 | |

EXAMINER**DATE CONSIDERED**

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached